Pittsburgh biotech names Alnylam exec as new chief commercial officer
Pittsburgh-based Krystal Biotech Inc. named a veteran biosciences executive as its new chief commercial officer.
Andy Orth will be in charge of launching Krystal’s medicines into the marketplace. He has 25 years of experience in the sector and had been SVP and head of U.S. business at Alnylam Pharmaceuticals, a Cambridge-based biopharmaceutical developer.
Krystal (Nasdaq: KRYS) is a Pittsburgh-based compa ny that has a platform that can create gene therapies to treat rare diseases where a gene…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Paul J. Gough Source Type: news
More News: American Health | Biotechnology | Gene Therapy | Genetics | Health Management | Rare Diseases